NCT06155604View on ClinicalTrials.gov

SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

January 4, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Lupus NephritisChronic Kidney Diseases
Interventions
DRUG

Dapagliflozin 10mg Tab

Dapagliflozin 10mg daily

DRUG

Standard maintenance therapy

Prednisolone 5-7.5 mg daily alone or in combination with Mycophenolate mofetil (\<=1.5 g/D) or Azathioprine (\<=150 mg/D)

Trial Locations (1)

Unknown

RECRUITING

Queen Mary Hospital, Hong Kong

All Listed Sponsors
lead

The University of Hong Kong

OTHER